Temporal relationship with the clinical benefits of clopidogrel therapy
|
Time interval (months) | Primary endpoint* |
ARR (%) |
RRR [95% CIs] (%) |
NNT (per month) | |
|
Clopidogrel (%) |
Placebo (%) | ||||
| CURE trial | |||||
| 0–1 | 4.3 | 5.5 | 1.2 | 22 [9, 32] | 84 |
| 1–3 | 1.8 | 2.5 | 0.8 | 32 [13, 46] | 240 |
| 3–6 | 1.8 | 1.8 | 0.0 | 4 [−27, 27] | 5174 |
| 6–9 | 1.3 | 1.4 | 0.1 | 6 [–34, 34] | 3171 |
| 9–12 | 1.1 | 1.3 | 0.2 | 14 [−32, 44] | 1600 |
| 0–12 | 10.3 | 12.6 | 2.4 | 19 | 507 |
| CHARISMA trial | |||||
| 0–28 | 6.8 | 7.3 | 0.5 | 7* | 5591 |
| Subgroup of patients with clinically evident atherosclerotic disease | |||||
| 0–28‡ | 6.9 | 7.9 | 1.0 | 12 | 2800 |
*Primary endpoint—cardiovascular death, myocardial infarction and stroke.
ARR, absolute risk reduction; CI, confidence intervals; CVD, cardiovascular death; MI, myocardial infarction; NNT, number needed to treat; RRR, relative risk reduction.